JAC Advance Access originally published online on June 3, 2006
Journal of Antimicrobial Chemotherapy 2006 58(2):332-337; doi:10.1093/jac/dkl227
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro
Sequella, Inc., 9610 Medical Center Drive Suite 200, Rockville, MD, 20850, USA
Received 12 December 2005; returned 22 February 2006; revised 28 March 2006; accepted 9 May 2006
*Correspondence address. Rm 4062, 6610 Rockledge Drive, MSC 6603, Bethesda, MD 20892-6603, USA. Tel: +1-301-451-3756; Fax: +1-301-402-2508; E-mail: chenpi{at}niaid.nih.gov
Objectives: The purpose of this study was to determine interactions of SQ109, a new asymmetric diamine tuberculosis (TB) drug candidate, with existing antitubercular drugs in vitro and assess its potential to improve combination drug activities against Mycobacterium tuberculosis.
Methods: Two-drug combinations at various concentrations below their MICs were tested for growth inhibition of M. tuberculosis using the BACTEC 460 system in vitro. Drug interactions were evaluated based on the quotient values that were derived numerically from the growth indices of cultures treated with a single antibiotic or combination treatment with two antibiotics.
Results: SQ109 at 0.5 of its MIC demonstrated strong Synergistic activity with 0.5 MIC isoniazid and as low as 0.1 MIC rifampicin in inhibition of M. tuberculosis growth. Additive effects were observed between SQ109 and streptomycin, but neither synergy nor additive effects were observed with the combination of SQ109 with ethambutol or pyrazinamide. The synergy between SQ109 and rifampicin was also demonstrated using rifampicin-resistant (RIFR) M. tuberculosis strains; SQ109 lowered the MIC of rifampicin for these drug-resistant strains.
Conclusions: SQ109 interacts Synergistically with isoniazid and rifampicin, two of the most important front-line TB drugs. This finding supports efforts to further evaluate new combination therapies containing SQ109 in experimental animal models of TB that emulate future clinical trial studies in humans.
Keywords: antibiotics , SQ109 , rifampicin , isoniazid , tuberculosis , Mycobacterium tuberculosis , in vitro , combination treatment , synergy
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. van den Boogaard, G. S. Kibiki, E. R. Kisanga, M. J. Boeree, and R. E. Aarnoutse New Drugs against Tuberculosis: Problems, Progress, and Evaluation of Agents in Clinical Development Antimicrob. Agents Chemother., March 1, 2009; 53(3): 849 - 862. [Full Text] [PDF]
|
|
|
|
 |
|
 E. S. Guy and A. Mallampalli Review: Managing TB in the 21st century: existing and novel drug therapies Therapeutic Advances in Respiratory Disease, December 1, 2008; 2(6): 401 - 408. [Abstract] [PDF]
|
|
|
|
|
|
H. Safi, B. Sayers, M. H. Hazbon, and D. Alland Transfer of embB Codon 306 Mutations into Clinical Mycobacterium tuberculosis Strains Alters Susceptibility to Ethambutol, Isoniazid, and Rifampin Antimicrob. Agents Chemother., June 1, 2008; 52(6): 2027 - 2034. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. V. Nikonenko, M. Protopopova, R. Samala, L. Einck, and C. A. Nacy Drug Therapy of Experimental Tuberculosis (TB): Improved Outcome by Combining SQ109, a New Diamine Antibiotic, with Existing TB Drugs Antimicrob. Agents Chemother., April 1, 2007; 51(4): 1563 - 1565. [Abstract] [Full Text] [PDF]
|
|